Moreover, the absence of ARPI benefit aligns with both preclinical studies and mCRPC clinical data which indicate that AVPC-TSG alterations may mediate resistance to hormonal treatments and docetaxel, with TP53, RB1, and PTEN loss driving prostate cancer progression and ARPI resistance. Here, RB1 is linked to Familial prostate cancer.